Your browser doesn't support javascript.
loading
Rethinking the marketing strategy of anti-tumor drugs by single-arm trials supported / 中华肿瘤杂志
Chinese Journal of Oncology ; (12): 587-592, 2022.
Article in Chinese | WPRIM | ID: wpr-940927
ABSTRACT
Single-arm trial refers to a clinical trial design that does not set up parallel control group, adopts open design, and does not involve randomization and blind method. These features, on the one hand, speed up the process of clinical trials, significantly shorten the time to market and meet the needs of patients with advanced malignancies, but also lead to the uncertainty of single-arm clinical trials themselves. Recently, the US Food and Drug Administration held a meeting of the oncologic drug advisory committee to discuss six tumor indications that have been accelerated approved, which once again triggered the discussion of single-arm trials. The basis of accelerated approval by single-arm trial is actually a compromise on the level of evidence-based medical evidence requirements after assessing the benefit risk. Therefore, the sponsor should strictly grasp the applicable conditions of single-arm trial in anti-tumor drugs and conduct single-arm trial scientifically. Post-marketing clinical trial should be implement as early as possible to ensure the benefit of patients. Based on the characteristics of single-arm trial, combined with two guidance relevant to single-arm trial issued by National Medical Products Administration recently, this article is supposed to propose and summarize the strategy of single-arm trial supporting the marketing of anti-tumor drugs.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Research Design / United States / United States Food and Drug Administration / Clinical Trials as Topic / Marketing / Neoplasms / Antineoplastic Agents Type of study: Controlled clinical trial / Practice guideline Limits: Humans Country/Region as subject: North America Language: Chinese Journal: Chinese Journal of Oncology Year: 2022 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Research Design / United States / United States Food and Drug Administration / Clinical Trials as Topic / Marketing / Neoplasms / Antineoplastic Agents Type of study: Controlled clinical trial / Practice guideline Limits: Humans Country/Region as subject: North America Language: Chinese Journal: Chinese Journal of Oncology Year: 2022 Type: Article